Please login to the form below

Not currently logged in
Email:
Password:

FDA approves 14 generic copies of GSK's Coreg

The FDA allows 14 generic manufacturers to sell first generic versions of GlaxoSmithKline's blood pressure drug Coreg in the US

The FDA has given 14 generic manufacturers permission to sell the first generic versions of GlaxoSmithKline's (GSK) blood pressure drug Coreg (carvedilol) on the US market.

The agency stated on 5 September 2007 that the companies, which included Caraco Pharmaceutical, Mylan, Ranbaxy and Watson, could sell generic versions of Coreg in strengths of 3.125 mg, 6.25 mg, 12.5 mg and 25 mg.

Coregis is approved in the US to treat high blood pressure, mild-to-severe chronic heart failure and left ventricular dysfunction following a heart attack.

GSK sells a newer, daily reformulation of the drug called Coreg CR, which is patent protected until 2023, according to the UK-based firm.

30th September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...

Infographics